The Company has completed a program that demonstrates that the BDS can deliver therapeutic doses of desmopressin, a peptide, for extended periods of time using our progressive hydration buccal technology. Based on these positive results, the Company has initiated partnering discussions related to a desmopressin buccal tablet for bed-wetting (nocturnal enuresis) in children. Related press release.
[Return to Research and Development Pipeline]
|
|